Drugs / SLC022
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00813826 | Jan → Oct 2009 | postherpetic neuralgia | Solace Pharmaceuticals | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SLC022 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00813826 ↗ |
| Route | Oral | “Oral SLC022 300 mg TID” NCT00813826 ↗ |